### This Page Is Inserted by IFW Operations and is not a part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.










FIG. 1B







GPV III

### FIG. 1E

Lag1NGA

Lag2CAR

Mok3ETP

| DEC 1 5 20 | IIa and the same a | •                |
|------------|--|------------------|
|            | 190  | \$1556000<br>\$1 |
|            | Ħ  | \$               |
|            |  | •                |
|            |  |                  |

ㅁ

130

----k-t---a-vp-i--s-----1-----k--m

--lasp--atc-p--

EBL1 FRA


EBL2FIN

Duv1SAF

EBL2HOL

Duv2SAF

| 7    |          |
|------|----------|
| FINO |          |
| Ç    | <u>5</u> |
| 117  | U        |
|      | j<br>j   |
|      |          |



# FIG. 1E (CONT. 2)


## FIG. 1E (CONT. 3)



### -e--t-dvrnttpstre --v--v--v----s--mr----f-n--ks--s-v--t---i-kgngpv-----e--t-dvrnttpstre 510 --ve-g-ds --ve-g-ds --h-r---v----s-gk-1+ms-g-r-1+1--v111-+r--nktgstqrghr-srg-m--ap-n--i-s---1--resetgl --her---v----n-gk-v+1s-g--ta-m-1-flmt-wr--n-septqh-1rgtg-e----p----i-s----s-getg1 DVQK-ISGIDLGLPEWKRYFLIGASALALLALAIIIAVCCKRVKRRR--KPNP-ELIRKVSVTSQSGKVIPSWESYK-GT-G ----sv-dv----h-gfw1-v--tvv+fvv--c11x---r-mr---slratqdiplsvapapvpra--vs---s-glpgt -i--l--dv----s-gl-vm---avi-f=v-1c1-xi--kkt-t-tsmer-dpp-slsttpgsra--vs----gssnv --h-sv-dv-----h-gfwm----tiv-fvv-vellz-----sgratgeiplsfp-apvpra--vs----glpgt --h-lv-dv-----d-sl-a---til-ffi-icl-tr--krg--nsptnr-dlp-glsttpqpks---s-------v--v--v---i-kgngpv----490 ---qv-----s--e--<u>laeetenvataeetenerer-r-r-r----kkartdri--d</u>-----t-a---sr---rp----i---470 450 -tngk-----430 -tngk----EBL1POL Lag1NGA USA7-BT Lag2CAR **EBL1FRA** Duv1SAF Duv2SAF EBL2FIN EBL2HOL


# FIG. 1E (CONT. 4)

留留



DEC 1 5 2003

FIG. 2A







FIG. 2B FIG. 2C








FIG. 2D FIG. 2E FIG. 2F









FIG. 2G FIG. 2H FIG. 2I

















FIG. 2J FIG. 2K FIG. 2L










FIG. 2N FIG. 20
















FIG. 5A







FIG. 5B









































FIG. 7C

FIG. 7D








FIG. 8A







FIG. 8B (CONT.)





F/G. 9





FIRST INJECTION / SECOND INJECTION





FIG. 10





CVS NEUTRALIZING ANTIBODY TITER: IU/ml (RFFIT)





FIG. 12



## FIG. 13B





## FIG. 13A



